Fecal calprotectin concentration in celiac disease

Journal of Clinical Gastroenterology

Volumn 44, Issue 8, 2010, Pages 544-546

  Ertekin, Vildan ^a   Selimoǧlu, Mukadder Ayşe ^b   Turgut, Ahmet ^a   Bakan, Nuri ^c  

^a ATATURK UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c ATATÜRK UNIVERSITY   (Turkey)

Author keywords

celiac disease; children; fecal calprotectin

Indexed keywords

CALGRANULIN;

ADOLESCENT; ARTICLE; CELIAC DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAILURE TO THRIVE; FECES ANALYSIS; FECES LEVEL; FEMALE; GLUTEN FREE DIET; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; INTESTINE VILLUS ATROPHY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; DIET, GLUTEN-FREE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SEVERITY OF ILLNESS INDEX;

EID: 77955931612     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181cadbc0     Document Type: Article

References (28)

1. Shamir R. Advances in celiac disease. Gastroenterol Clin North Am. 2003;32:931-947.
2. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ("celiac sprue"). Gastroenterology. 1992;102:330-354.
3. Kagnoff M. Overview and pathogenesis of celiac disease. Gastroenterology. 2005;128(suppl 1):S10-S18.
4. Aadland E, Fagerhol MK. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:823-825.
5. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol. 1980; 24:393-398.
6. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113-123.
7. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180.
8. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171-177.
9. Working Group of European Society of Paediatric Gastroenterology and Nutrition. Revised criteria for diagnosis of celiac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child. 1990;65:909-911.
10. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185-1194.
11. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-647.
12. Berni CR, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467-470.
13. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49: 861-867.
14. Montalto M, Santora L, Curigliano V, et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol. 2007;42:957-961.
15. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
16. Shitrit AB, Braverman D, Stankiewics H, et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum. 2007;50:2188-2193.
17. Fagerberg UL, Lööf L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420.
18. Bremner A, Roked S, Robinson R, et al. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855-1858.
19. Hallgren R, Colombel JF, Dahl R, et al. Neutrophil and eosinophil involvement of small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am J Med. 1989;86:56-64.
20. Ensari A, Marsh MN, Loft DE, et al. Morphometric analysis of intestinal mucosa. V. Quantitative histological and immunocytochemical studies of rectal mucosae in gluten sensitivity. Gut. 1993;34:1225-1229.
21. Breen EG, Coughlan G, Connolly CE, et al. Coeliac proctitis. Scand J Gastroenterol. 1987;22:471-477.
22. Kristjansson G, Serra J, Loof L, et al. Kinetics of mucosal granulocyte activation after gluten challenge in coeliac disease. Scand J Gastroenterol. 2005;40:662-669.
23. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol. 2000;35:64-69.
24. Vilela EG, De Abreu Ferrari Mde L, De Gama Torres HO, et al. Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease. Dig Dis Sci. 2007; 52:1304-1309.
25. Vogelsang H, Schwarzenhofer M, Steiner B, et al. In vivo and in vitro permeability in coeliac disease. Aliment Pharmacol Ther. 2001;15:1417-1425.
26. Vogelsang H, Schwarzenhofer M, Oberhuber G. Changes in gastrointestinal permeability in celiac disease. Dig Dis. 1998;16: 333-336.
27. Perry I, Iqbal T, Cooper B. Intestinal permeability in coeliac disease. Lancet. 2001;358:1729-1730.
28. Bjarnasson I, Peters TJ. A persistent defect in intestinal permeability in coelic disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet. 1983;12:323-325.